Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety

Detalhes bibliográficos
Autor(a) principal: Correia, Eduardo Thadeu de Oliveira
Data de Publicação: 2020
Outros Autores: Barbetta, Letícia Mara dos Santos, Almeida, João Paulo Chevrand Latini de, Mesquita, Evandro Tinoco
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da Universidade Federal Fluminense (RIUFF)
Texto Completo: http://app.uff.br/riuff/handle/1/29065
Resumo: Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
id UFF-2_d18d658b9ad364fb3ca75fb73c6e0b07
oai_identifier_str oai:app.uff.br:1/29065
network_acronym_str UFF-2
network_name_str Repositório Institucional da Universidade Federal Fluminense (RIUFF)
repository_id_str 2120
spelling Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safetyAnakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safetyAnakinraInterleukin-1 receptor antagonistRecurrent pericarditisPericarditeInterleucina-1AnakinraInterleukin-1 receptor antagonistRecurrent pericarditisAnakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.SimAnakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.Taylor WalkerNiterói, RJ2023-06-06T15:00:43Z2023-06-06T15:00:43Z2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfCORREIA, Eduardo Thadeu de Oliveira. Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness, and safety. Journal of Cardiovascular Pharmacology, v. 76, n. 1, p. 42-49, Jul. 2020. Disponível em: https://journals.lww.com/cardiovascularpharm/Fulltext/2020/07000/Anakinra_in_Recurrent_Pericarditis__Current.5.aspxhttp://app.uff.br/riuff/handle/1/29065Aluno de Graduação10.1097/FJC.0000000000000839JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. Jackson, MS: Taylor Walker, 1979-. Mensal. ISSN: 1533-4023CC-BY-SAinfo:eu-repo/semantics/openAccessCorreia, Eduardo Thadeu de OliveiraBarbetta, Letícia Mara dos SantosAlmeida, João Paulo Chevrand Latini deMesquita, Evandro Tinocoengreponame:Repositório Institucional da Universidade Federal Fluminense (RIUFF)instname:Universidade Federal Fluminense (UFF)instacron:UFF2023-06-06T15:00:46Zoai:app.uff.br:1/29065Repositório InstitucionalPUBhttps://app.uff.br/oai/requestriuff@id.uff.bropendoar:21202023-06-06T15:00:46Repositório Institucional da Universidade Federal Fluminense (RIUFF) - Universidade Federal Fluminense (UFF)false
dc.title.none.fl_str_mv Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
title Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
spellingShingle Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
Correia, Eduardo Thadeu de Oliveira
Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
Pericardite
Interleucina-1
Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
title_short Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
title_full Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
title_fullStr Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
title_full_unstemmed Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
title_sort Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness and safety
author Correia, Eduardo Thadeu de Oliveira
author_facet Correia, Eduardo Thadeu de Oliveira
Barbetta, Letícia Mara dos Santos
Almeida, João Paulo Chevrand Latini de
Mesquita, Evandro Tinoco
author_role author
author2 Barbetta, Letícia Mara dos Santos
Almeida, João Paulo Chevrand Latini de
Mesquita, Evandro Tinoco
author2_role author
author
author
dc.contributor.author.fl_str_mv Correia, Eduardo Thadeu de Oliveira
Barbetta, Letícia Mara dos Santos
Almeida, João Paulo Chevrand Latini de
Mesquita, Evandro Tinoco
dc.subject.por.fl_str_mv Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
Pericardite
Interleucina-1
Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
topic Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
Pericardite
Interleucina-1
Anakinra
Interleukin-1 receptor antagonist
Recurrent pericarditis
description Anakinra is a recombinant human interleukin 1 receptor antagonist that competes and blocks the biologic effects of interleukin 1, reducing systemic inflammatory responses. In the 2015 guidelines for the diagnosis and management of pericardial diseases of the European Society of Cardiology, anakinra was established as a third-line therapy option for refractory recurrent pericarditis (RP). Recently, important studies that investigates the effect and safety of anakinra in RP were published, such as the AIRTRIP trial and the International Registry of Anakinra for Pericarditis. This article presents the current evidence about the effectiveness and safety of anakinra in RP and discusses its clinical application and mechanisms.
publishDate 2020
dc.date.none.fl_str_mv 2020
2023-06-06T15:00:43Z
2023-06-06T15:00:43Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv CORREIA, Eduardo Thadeu de Oliveira. Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness, and safety. Journal of Cardiovascular Pharmacology, v. 76, n. 1, p. 42-49, Jul. 2020. Disponível em: https://journals.lww.com/cardiovascularpharm/Fulltext/2020/07000/Anakinra_in_Recurrent_Pericarditis__Current.5.aspx
http://app.uff.br/riuff/handle/1/29065
Aluno de Graduação
10.1097/FJC.0000000000000839
identifier_str_mv CORREIA, Eduardo Thadeu de Oliveira. Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness, and safety. Journal of Cardiovascular Pharmacology, v. 76, n. 1, p. 42-49, Jul. 2020. Disponível em: https://journals.lww.com/cardiovascularpharm/Fulltext/2020/07000/Anakinra_in_Recurrent_Pericarditis__Current.5.aspx
Aluno de Graduação
10.1097/FJC.0000000000000839
url http://app.uff.br/riuff/handle/1/29065
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. Jackson, MS: Taylor Walker, 1979-. Mensal. ISSN: 1533-4023
dc.rights.driver.fl_str_mv CC-BY-SA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv CC-BY-SA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor Walker
Niterói, RJ
publisher.none.fl_str_mv Taylor Walker
Niterói, RJ
dc.source.none.fl_str_mv reponame:Repositório Institucional da Universidade Federal Fluminense (RIUFF)
instname:Universidade Federal Fluminense (UFF)
instacron:UFF
instname_str Universidade Federal Fluminense (UFF)
instacron_str UFF
institution UFF
reponame_str Repositório Institucional da Universidade Federal Fluminense (RIUFF)
collection Repositório Institucional da Universidade Federal Fluminense (RIUFF)
repository.name.fl_str_mv Repositório Institucional da Universidade Federal Fluminense (RIUFF) - Universidade Federal Fluminense (UFF)
repository.mail.fl_str_mv riuff@id.uff.br
_version_ 1807838680708022272

Registros relacionados